Tara Graff, DO

Dr. Lunning acknowledges country-specific cost-access realities for novel therapies, noting he prescribes what the evidence supports and then navigates insurance processes including peer-to-peer reviews when needed.

Dr. Graff addresses the persistent gap between the CAR-T evidence base and real-world utilization.

Dr. Johnson discusses the FDA's April 2026 update to the epcoritamab label permitting outpatient monitoring for the first full 48 mg dose in relapsed/refractory DLBCL.

Dr. Graff reviews the EPCORE DLBCL-1 Phase 3 trial comparing epcoritamab monotherapy against investigator's choice of R-GemOx or bendamustine-rituximab in relapsed/refractory DLBCL.

Dr. Johnson addresses whether using CD19-directed agents in the frontline compromises subsequent relapse options.

Dr. Graff discusses the challenging scenario of a positive interim PET scan mid-treatment.

Dr. Johnson confirms dose-adjusted R-EPOCH as his standard for the vast majority of double-hit patients outside clinical trials, noting POLARIX and frontMIND each included only approximately 6% to 8% double-hit patients, far too few for meaningful subgroup analysis.

Dr. Graff addresses whether the absence of overall survival benefit from either POLARIX or frontMIND should discourage adoption.

Dr. Lunning discusses decision-making when both Pola-R-CHP and Tafa-Len-R-CHOP are options.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.

An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.

Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.

A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.

Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.